Natixis Investment Managers International Bluebird Bio, Inc. Transaction History

Natixis Investment Managers International

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $173,163 - $273,251	-2,930 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $260,448 - $344,363	-2,931 Reduced 50.01%	2,930 $428,000
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $300,789 - $429,122	2,843 Added 94.2%	5,861 $1 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $520,893 - $837,917	-6,411 Reduced 67.99%	3,018 $538,000
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $384,837 - $609,314	6,665 Added 241.14%	9,429 $1.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,764	2,764 $290,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $29.3M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

Stay updated on Natixis Investment Managers International with notifications on news.